Article Information
History
- February 1, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Janev Fehmi, MBBS1,
- Alexander J. Davies, PhD1,
- R. Jon Walters, MD2,
- Tim Lavin, MBBS3,
- Ryan Keh, MBBCHIR3,
- Alexander M. Rossor, FRCP, PhD4,
- Tudor Munteanu, MD5,
- Norman Delanty, MB5,
- Rhys Roberts, PhD6,
- Dirk B□umer, DPhil6,
- Graham Lennox, BM, BCh7 and
- Simon Rinaldi, PhD1,*
- 1Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK
- 2Department of Neurology, Morriston Hospital, Morriston, Swansea, Wales SA6 6NL, UK
- 3Manchester Centre for Clinical Neuroscience, Salford Royal NHS Foundation Trust, UK
- 4MRC Centre for Neuromuscular Disease, National Hospital of Neurology and Neurosurgery and Department of Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK
- 5Beaumont Hospital, Dublin, Ireland
- 6Department of Clinical Neurosciences, Cambridge Institute for Medical Research, UK
- 7Department of Neurology, Great Western Hospital, Swindon, UK
- ↵*Corresponding author: Dr Simon Rinaldi
, Nuffield Department of Clinical Neurosciences, University of Oxford, Level 6, West Wing, John Radcliffe Hospital, Oxford, UK. OX3 9DU., (simon.rinaldi{at}ndcn.ox.ac.uk)
Posted February 01, 2021.
IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality
